



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 07-10-2009

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 04-09-2009 TO BE PUBLISHED \_\_\_\_\_ IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Muhammad Nabi-ur-Rehman)**

Assistant Controller

Ph: 9215500

**ENCL:**

## **NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

### **31-08-2009**

798/2009	Vifor (International) AG, Switzerland (Priority 29-09-2008 Europe)	“Receptacle and method for storing and supplying a liquid and a liquid medical preparation”
799/2009	CJ Cheiljedang Corporation, Korea (Priority 02-12-2008 Korea)	“Novel bacteriophage and antibacterial composition comprising the same”
800/2009	Sanofi-Aventis, France (Priority 02-09-2008 Europe)	“Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof”
801/2009	Otsuka Pharmaceutical Co., Ltd., Japan (Priority 05-09-2008 Japan)	Pharmaceutical solid preparation”
802/2009	Vifor (International) AG, Switzerland (Priority 29-09-2008 Europe)	“Cap Assembly and production method”
803/2009	Boehringer Ingelheim International GmbH, Germany (Priority 02-09-2008 Europe)	“Novel benzamides, their production and their use as medicament”
804/2009	Boehringer Ingelheim International GmbH, Germany (Priority 02-09-2008 Europe)	“Novel heteroaryl carboxamides, their production and their use as a medicament”

### **01-09-2009**

805/2009	Novartis AG, Switzerland (Priority 02-09-2008 USA)	“Kinase Inhibitors”
----------	--	---------------------

- |          |  |   |
|----------|--|---|
| 806/2009 | Banyu Pharmaceutical Co.,<br>Ltd.,<br>Japan<br>(Priority 06-10-06 Japan)<br>DIVISIONAL | “A pharmaceutically acceptable salt of a substituted 2-pyridine-carboxamide compound” |
| 807/2009 | Omer Khawaja,<br>Anwar Khawaja Industries,<br>(Pvt) Limited,<br>Sialkot, Pakistan      | “Outer cover of inflatable bladders for balls”  |
| 808/2009 | Nouman Idris Butt,<br>Sialkot, Pakistan  | “Nibb mega panels (outer cover of ball productions system)”                           |

**02-09-2009**

- |          |  |   |
|----------|--|---|
| 809/2009 | Otsuka Pharmaceutical Co.,<br>Limited,<br>Japan<br>National University<br>Corporation Gunma<br>University,<br>Japan<br>(Priority 04-03-2008 Japan) | “Cholestanol derivative for combined use” |
| 810/2009 | Otsuka Pharmaceutical Co.<br>Ltd.,<br>Japan<br>(Priority 23-02-05 Japan)<br>DIVISIONAL   | “Tea beverage”                            |
| 811/2009 | Takeda Pharmaceutical<br>Company Limited,<br>Japan<br>(Priority 06-02-2009 Japan)  | “Heterocyclic compound”                   |
| 812/2009 | Syngenta Participations AG,<br>Switzerland<br>(Priority 04-09-2008 UK)   | “Insecticidal Compounds”                  |

**03-09-2009**

- |          |  |                           |
|----------|--|---------------------------|
| 813/2009 | Priaxon AG,<br>Germany<br>(Priority 15-09-2008 Europe) | “Novel pyrrolidin-2-ones” |
|----------|--|---------------------------|

814/2009	Acucela, Inc., USA (Priority 05-09-2008 USA)	“Sulphur-linked compound for treating ophthalmic diseases and disorders”
815/2009	Novatec Biosol AG, Germany (Priority 03-09-2008 Europe)	“Solar thermal energy plant”
<b><u>04-09-2009</u></b>		
816/2009	Omer Khawaja, M/S. Anwar Khawaja, industries (Pvt) Ltd., Sialkot, Pakistan.	“A composite hockey stick with multiple airinlet/cavity system”
817/2009	GlycoNex Inc, Taiwan (Priority 07-09-2008 USA)	“Anti-extended type 1 glycosphingolipid antibody, derivatives thereof and use”
818/2009	FLSmith A/S, Denmark (Priority 17-09-2008 Denmark)	“Rotary kiln for alternative fuels”
819/2009	Intelligent Engineering (Bahamas) Limited, Bahamas, (Priority 12-09-2008 UK)	“A stepped structure”
820/2009	Ardea Biosciences, Inc. USA. (Priority 04-09-2008 USA)	“Compounds, compositions and methods of using same for modulating uric acid levels”
821/2009	Ardea Biosciences, Inc., USA (Priority 04-09-2008 USA)	“Compounds, compositions and methods of using same for modulating uric acid levels”
822/2009	Elan Pharmaceuticals, Inc., USA (Priority 05-09-2008 USA)	“N-sulfonamido polycyclic pyrazolyl compounds”

**APPLICATION ACCEPTED**

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

148/2000	Smithkline Beecham p.l.c., England	“A composition comprising a combination of a thiazolidinedione maleate and an insulin secretagogue”
----------	--	---

**140245**


A pharmaceutical composition useful in the treatment of diabetes mellitus or a condition associated with diabetes mellitus, comprising a pharmaceutical ly acceptable carrier, 2 to 12 mg of the maleate salt of 5-[4-j\_2-(N-methyl)-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)), and an insulin secretagogue.

798/2000	Syngenta Participations AG, Switzerland	“A herbicidal composition comprising A 3-hydroxy-4(4-methylphenyl)-5-oxo-pyrazoline”
----------	---	--

A01N 43/48

**140246**

A selective herbicidal composition for controlling grasses and weeds in crops of cultivated plants, comprising: a) a herbicidally effective amount of a compound of formula (I),



wherein the substituents are defined as given in claim (1); b) a herbicidally synergistic amount of at least one herbicide selected from the classes of phenoxy-phenoxypropionic acids, hydroxylamines, sulfonylureas, imidazolinones, pyrimidines, triazines, ureas, PRO, chloroacetanilides, phenoxyacetic acids, triazinones, dinitroanilines, azinones, carbamates, oxyacetamides, thiolcarbamates, azole-ureas, benzoic acids, anilides, nitriles, triones and sulfonamides, as well as from the herbicides amitrol, benfuresate, bentazone, cinmethylin, clomazone, chlopyralid, difenzoquat, dithiopyr, ethofumesate, flurochloridone, indanofane, isoxaben, oxaziclomefone, pyridate, pyridafol, quinchlorac, quinmerac, tridiphane and flamprop; and optionally c) to antagonise the herbicide, and antidotally effective amount of a safener selected from cloquintocet, an alkali, alkaline earth, sulfonium or ammonium cation of cloquintocet, cloquintocet-mexyl, mefenpyr, an alkali, alkaline earth, sulfonium or ammonium cation of mefenpyr and mefenpyr-diethyl; and/or d) an additive comprising an oil of vegetable or animal origin, a mineral oil, the alkylesters thereof or mixture<sup>^</sup> of these oils and oils.

333/2001 Bayer CropScience  
AG,  
Germany

“Liquid composition comprising sulfosuccinate”

A01N 47/36

**140247**

The present invention relates to liquid composition (preparations) comprising a) one or more compound of polycarboxylic acids and b) one or more active compound from the group of

the ALS inhibitors.


821/2001 Mitsubishi Tanabe  
Pharma Corporation,  
Japan

“A phenylalanine compound”

C07C 229/00

140248

The present invention relates to a phenylalanine compound of Formula [ I ]:



wherein X<sup>1</sup> is a halogen atom, X<sup>2</sup> is a halogen atom, Q is a -CH<sub>Z</sub>- group or a -(CH<sub>3</sub>)<sub>2</sub>- group, Y is a C<sub>1-6</sub> alkyl group, and CO<sub>2</sub>R is a carboxyl group which may be esterified.


1043/2003 AstraZeneca UK  
Limited,  
UK

“Pyrimidine compound”

A61K 31/505, C07D 239/69

140249

A compound of formula (2a), and tautomer thereof:



Formula (2a)

wherein

R<sup>1</sup> is H or an alkyl group;

R<sup>2</sup> is H or an alkyl or aryl group;

R<sup>3</sup> and R<sup>4</sup> are each independently H, alkyl or aryl, provided that R<sup>3</sup> and R<sup>4</sup> are not both unsubstituted alkyl; and

E is an unsubstituted alkyl group, further

provided that R<sup>1</sup> is not -CH<sub>3</sub> when R<sup>2</sup> is unsubstituted phenyl or o-nitrophenyl.

982/2004 Syngenta  
Participations AG,  
Switzerland

“A pesticide concentrate comprising an ionic nitrate salt additive as the preparation of compositions for controlling pests”

A01N 41/10

**140250**

The present invention relates to aqueous-containing pesticide concentrates containing an ionic nitrate salt additive as a corrosion inhibitor as well as pesticide compositions prepared from these concentrates and to the use of said compositions for controlling pests.


1061/2004 Eli Lilly and  
Company,  
USA

“Substituted imidazo[4,5-B]pyridine-2-ylamine compound”

C07D 471/04, A61K 31/4188, A61P 29/00

**140251**

The present invention provides a compound of formula I:



I

as kinase inhibitor.

83/2005 F.L. Smith A/S,  
Denmark

“Method and apparatus for hydration of a particulate or pulverant material containing CaO, hydrated product, and use of the hydrated product”

C01F 11/02, C04B 2/04

**140252**

Described is a method as well as an apparatus for hydration of a particulate or pulverulent material

containing CaO. The method is peculiar in that water is added in a quantity which will ensure that the partial pressure  $P_{H_2O}$  of the added water as a function of the temperature ( $^{\circ}C$ ) is maintained within the interval defined by the formula

$$6,85 - \frac{5459}{(T + 273)} < \log P_{H_2O} < 5,45 - \frac{2032}{(T + 273)},$$

here  $P_{H_2O}$  is the partial pressure of water vapour in atm. and T is the temperature in  $^{\circ}C$ . Hereby is obtained that the material particles do not lump into agglomerates, and that the particles are hydrated evenly from the outside and inwards so that it is the active surface of the material particles which undergoes hydration in connection with partial hydration. This is due to the fact that the liquid water will not get into contact with the material particles since the water will appear in vapour form within the specified interval.

1041/2005 Lurgi Zimmer  
GmbH,  
Germany

“Method for manufacturing polyester and ring disc reactor suitable for this purpose”

C08G 63/81, B01J 19/18, C08G 63/78

### 140253

A method and a device for manufacturing polyester such as polyethylene, polypropylene, and polyethylene terephthalate starting from precondensates is described, in which vapors having corosol type distributed precondensate particles are conducted through a polycondensation reactor, in which precondensate components are deposited on the reactor wall and an outlet chamber of the reactor on a depositing device, the deposits being conducted to the unstirred discharge sump and the upper layers of the discharge sump continuously being recirculated in the stirred reactor area and therefore being subjected to back-mixing and further polycondensation.

1099/2005 Novozymes A/S,  
Denmark

“Polypeptide having antimicrobial activity and polynucleotide encoding same”

C12N 15/80, C07K 14/415, A61K 38/16

**140254**

The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as method for producing and using the polypeptides.

264/2006 Syngenta  
Participations AG.,  
Switzerland

“A method for controlling harmful plants in a rice crop”

A01N 35/06

**140255**

A method for selectively controlling weeds in rice, in particular weeds in transplanted and direct-seeded rice, using a 2-benzoyl-1,3-cyclohexanedione derivatives, in particular mesotrione, is disclosed.


1177/2006 AstraZeneca UK  
Limited,  
UK

“Process for the preparation of pyrimidine  
compound”

C07D 295/04

**140256**

A process for the preparation of a compound of  
Formula (2a) and tautomer thereof:



**Formula (2a)**

which comprises

reacting a compound of formula R<sup>1</sup>-CO-CH<sub>2</sub>-E  
with a compound of formula R<sup>2</sup>-CHX<sup>1</sup>X<sup>2</sup> in the  
presence of a compound of formula R<sup>3</sup>R<sup>4</sup>N-  
C(=NH)NH<sub>2</sub> and a catalyst, thereby to form the  
compound of formula (2a)

wherein

R<sup>1</sup> is an H or an alkyl group;

R<sup>2</sup> is an H or an aryl or aryl group;

R<sup>3</sup> and R<sup>4</sup> are each independently H, alkyl or aryl,  
or R<sup>3</sup> and R<sup>4</sup> are linked to form, together with the  
nitrogen to which they are attached to form a 5 to  
7 membered heterocyclic ring;

E is H, an unsubstituted alkyl group, an aryl  
group or an electron withdrawing group; and X<sup>1</sup>  
and X<sup>2</sup> are each independently leaving groups, or  
X<sup>1</sup> and X<sup>2</sup> together represent =O.


1178/2006 AstraZeneca UK  
Limited,  
UK

“Process for the preparation of pyrimidine  
compound”

C07D 239/69

**140257**

A process for the preparation of a compound of  
Formula (3):




**Formula (3)**

which comprises

a) reacting a compound of formula  $R^1\text{-CO-CIfe-E}$  with

a compound of formula  $R^2\text{-CHX}^2$  in the presence of a compound of formula  $R^7\text{HN-C(=NH)NH}_2$  and a catalyst, thereby to form a dihydropyrimidine;

b) oxidising the dihydropyrimidine produced in step a) to form a compound of Formula (4)



**Formula (4)**

and

c) reacting the compound of Formula (4) with a compound of formula  $R^6\text{SOa-X}^4$  to give a compound of Formula (3); wherein  $R^1$ ,  $R^2$ ,  $E$ ,  $X^1$  and  $X^2$  are as defined in claim 1;  $R^6$  represents alkyl or aryl, preferably methyl;  $R^7$  is H, alkyl or aryl; and  $X^4$  represents a leaving group, preferably Cl or Br.

1084/2006 Novartis AG,  
Switzerland


“Method of preparation of (imidazol-2-yl-pyridin-4-yloxy)-1h-benzimidazole-2-yl amine”

C07D 401/14

**140258**

Method for preparing new substituted

benzimidazole compound having formula (I) useful for treating kinase mediated disorders are provided wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , a, b, and c are defined herein.




1138/2006 Mitsubishi Pharma  
Tanabe Corporation,  
Japan

“Salt of phenylalanine compound”

C07C 229/00

**140259**

The present invention relates to a phenylalanine compound of formula (I):



Wherein  $x^1$  is a halogen atom,  $x^2$  is a halogen atom, Q is a  $-CH_2-$  group or a  $-(CH_2)_2-$  group, Y is a  $C_{1-6}$  alkyl group; and  $CO_2R$  is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.

302/2007 Atlas Elektronik  
GmbH,  
Germany

“Method for determination of the instantaneous position of an acoustic section which is towed at a selected towing depth of a towed-array antenna”

G01V 1/38

**140260**

The invention relates to a method for determination of the instantaneous position of an acoustics section of a towed-array antenna (11) which is towed in the water by a towing vehicle (10) and has a deployed length. When using a

towed-array antenna, e.g. for detecting sound-emitting or sound reflecting targets, it is important to determine the position and the alignment of the acoustics section.

In order to determine a sufficiently accurate position without any additional hardware complexity and without demanding computation power, the position of the acoustics section is fixed at at least one selected point (14) in the acoustics section, and the position (Pt<sub>2</sub>) of the selected point (14) is estimated by means of a model from the positions (Ot<sub>1</sub>, Pt<sub>1</sub>) assumed by the towing vehicle (10) and the selected point (14) at the start of the movement (19) and from the position (Ot<sub>2</sub>) assumed by the towing vehicle (10) at the end of the movement (19), including the deployed length (L) of the towed-array antenna and the towing depth of the acoustics section.

The method features the advantage of providing a practicable determination of the instantaneous position and of the alignment of the acoustics section of the towed-array antenna with little computation complexity resulting in a quick determination.




Fig. 4


619/2007 Glaxo Group  
Limited,  
UK

“Substituted 4-pyridone compound”

C07D 213/68

140261

4-pyridone (4-pyridinone) derivatives of formula I



processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.

740/2007 Otsuka  
Pharmaceutical Co.,  
Ltd., Japan  
Otsuka Techno  
Corporation,  
Japan

“Powder inhaler for supplying multiple doses of a powdered pharmaceutical drug”


A61M 15/00

**140262**

[Object] To provide a powder inhaler which enables the completion of an entire inhalation process by fewer operations than are conventionally necessary, and is hence more convenient for users.

[Means for Achieving the Object] A powder inhaler has a housing having a mouthpiece opening at one end thereof; a supply member mounted in the housing, having a volume capable of holding multiple doses of a powdered drug, and having a drug discharge aperture; a drug carrier disposed in the housing 1A, having a measuring recess to receive the equivalent of one dose of the drug from the drug discharge aperture, the measuring recess supported so as to move freely between a drug receiving position where the measuring recess can receive the drug from the drug discharge aperture and a drug inhalation position where the drug received in the measuring recess can be inhaled from the mouthpiece opening; a cover cap C2 swingably attached to the housing 1A; and a means for imparting vibration to the supply member, actuated by the swinging of the cover cap C2.

Fig-18




1287/2007 Mr. Yoshio Oyama,  
Japan

“An ampoule guide and a drug solution  
administering unit”

A61J 1/05, A61M 5/30

**140263**

An object of the present invention is to provide an ampoule guide and drug solution administering unit having excellent stability. An above object is an ampoule guide (30) comprising a hollow cylindrical guard (31) which is provided at tipping portion, the ampoule guide being capable of accommodating therein an ampoule (20), characterized in that, the ampoule guide (30) further comprises a plurality of projections (33) in a direction parallel to central axis (5) of the ampoule (20), wherein some of the projections are taller than their surrounding projections, the taller projections being provided at an angular intervals of any one of 60 degrees, 90 degrees, 120 degrees, and 180 degrees.




104/2008 Boehringer  
Ingelheim  
International GmbH,  
Germany

“A process for preparing the compound for the synthesis of the pharmaceutical active substance dabigatran etexilate”

C07D 401/12

**140264**

The invention relates to a process for preparing the compound of formula 1.



a valuable intermediate product in the synthesis of the pharmaceutical active substance dabigatran etexilate.


250/2008 Eli Lilly and  
Company,  
USA

“5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazol[4,5-b]pyridine-2-ylamine dimethanesulfonate compound”

C07D 471/04, A61K 31/4188, A61P 29/00

**140265**

The present invention provides a compound 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazol[4,5-b]pyridin-2-ylamine dimethanesulfonate represented by the formula




534/2008 Eli Lilly and  
Company,  
USA

“Triazolyl aminopyrimidine compound”

A61P 35/00, C07D 409/14, A61K 31/506

**140266**

The present invention provides a compound for  
formula I



useful in the treatment of cancer.


536/2008 Eli Lilly and  
Company,  
USA

“Triazolyl aminopyrimidine compound”

A61K 31/506, C07D 409/14, A61P 35/00

**140267**

The present invention provides a compound for  
formula I



useful in the treatment of cancer.


836/2008 Eli Lilly and Company, USA

“Substituted isoxazol-4-ylmethoxy-piperidin-1-ylbiphenyl-2-carboxylic acid compound”

C07D 261/08, C07D 413/12, A61K 31/42, A61P 3/06

**140268**

Compound of formula



wherein variables are as defined herein and its pharmaceutical composition and method of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.


920/2008 Eli Lilly and Company, USA

“Substituted 1H-pyrazole-tetrahydro-[1,2']bipyrazinyl-4-yl-ethyl-methyl-amide compound”

C07D 241/20, C07D 403/14, C07D 409/12, A61K 31/497, A61P 25/06

**140269**

The present invention provides a selective 5-HT<sub>7</sub> receptor antagonist compound of Formula I:



where A is -C(H)= or -N=; m is 0, 1 or 2; R<sup>1</sup> is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyridyl, or thienyl; R<sup>2</sup> is hydrogen or methyl; and R<sup>3</sup> and R<sup>4</sup> are as defined herein, and a pharmaceutical composition comprising thereof for the treatment of migraine.


1117/2008 Sanofi-Aventis,  
France

“Substituted (cyclopropylphenyl)  
phenyloxalamide compound”

A61P 25/28, A61P 5/50, A61P 25/18, A61K,  
31/165, C07C 233/56, C07C 233/88

**140270**

The invention relates to a compound of the  
formula I



I

in which R1, R2, R3, R4, R5, R6, R7, R8 and m  
have the indicated meanings. The compound I  
suitable for example for the treatment of diabetes.

1387/2008 Honda Motor Co.,  
Ltd.,  
Japan


“Vehicle front body structure”

B60R 21/16

**140271**

Overlapping section (81) is constructed by  
positioning an inner side wall portion (78) of an  
outer impact absorbing section (63) closer to a

longitudinal centerline (48) of a vehicle body than an outer side wall (33, 103) of a front side frame (11, 12; 91), so that a collision impact load can be transmitted to the outer side wall portion by way of the overlapping section. Inner impact absorbing section (62) projects forward by a greater length than an outer impact absorbing section (63). Thus, an airbag-deploying acceleration threshold value  $G_s$  is set within a range between an acceleration level when the inner impact absorbing section (62) alone is deformed by impact energy and an acceleration level when the inner and outer impact absorbing sections (62, 63) are deformed. Fig. 5.




60/2009 AstraZeneca UK Limited, UK

“Process for the preparation of pyrimidine compound”

C07D 239/69

140272

A process for the preparation of a compound of Formula



and Intermediates useful therein are provided. The process comprises reacting a compound of formula  $R^1\text{-CO-CH}_2\text{-E}$  with a compound of formula  $R^a\text{-CHX}^1\text{X}^2$  in the presence of a compound of formula  $R^3R^4\text{N-C(=NH)NH}_2$  and a catalyst, thereby to form a dihydropyrimidine; and oxidising the dihydropyrimidine to form the compound of Formula (1).  $R^1$  is H or an alkyl group;  $R^2$  is H, an alkyl or aryl group;  $R^3$  and  $R^4$  are each independently H, alkyl or aryl, or  $R^3$  and  $R^4$  are linked to form, together with the nitrogen to which they are attached to form a 5 to 7 membered heterocyclic ring; E is H, an unsubstituted alkyl group, an aryl group or an electron withdrawing group; and  $X^1$  and  $X^2$  are each independently leaving groups, or  $X^1$  and  $X^2$  together represent =O.


788/2009 Eli Lilly and Company, USA

“A pharmaceutically acceptable salt of a substituted 1H-pyrazole-tetrahydro-[1,2']bipyrazinyl-4-YL-ethyl-methyl-amide compound”

C07D 241/70, C07D 403/14, C07D 409/12, A61K 31/497

**140273**

The present invention provides a pharmaceutically acceptable salt of a selective 5-HT<sub>7</sub> receptor antagonist compound of Formula I:



where A is -C(H)= or -N=; m is 0, 1 or 2;  $R^1$  is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyridyl, or

thienyl;  $R^2$  is hydrogen or methyl; and  $R^3$  and  $R^4$  are as defined herein, and a pharmaceutical composition comprising thereof for the treatment of migraine.

### SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139931	Janssen Pharmaceutica N.V., Belgium	1066/1999
139932	Syngenta Participations AG., Switzerland	975/2004
139933	Honda Motor Co. Limited, Japan	876/2005
139934	Unilever PLC., United Kingdom	1005/2005
139935	Boehringer Ingelheim International GmbH., Germany	1042/2005
139936	Reckitt Benckiser (Australia) PTY Limited, Australia	384/2006
139937	BDI Bio-Diesel International AG, Austria	821/2006
139938	Honda Motor Co. Limited, Japan	1215/2006
139939	Astrazeneca AB, Sweden	1358/2006
139940	Merck, Co. Inc., USA	1564/2006
139941	Merck Patent GmbH, Germany	521/2007
139942	Taisho Pharmaceutical Co. Limited, Japan	562/2007
139943	Dr. Mansoor Ahmad. Department of Pharmacognosy, University of Karachi, Pakistan	586/2007

139944	SMS Demag AG., Germany	603/2007
139945	Muhammad Yasin Khan, Chichawatini, Pakistan	815/2007
139946	Sanofi-Aventis, France	917/2007
139947	Eli Lilly and Company, USA	1341/2007
139948	AstraZeneca AB, Sweden	566/2008
139949	Eli Lilly and Company, USA	162/1996
139950	SmithKline Beecham p.l.c. England	341/2000
139951	Mitsubishi Tanabe Pharma Corporation, Japan	139/2003
139952	Wyeth, USA	150/2003
139953	Chiesi Farmaceutici SPA, Italy	157/2003
139954	Novartis AG., Switzerland	164/2003
139955	Aventis Pharma S.A., France	994/2004
139956	De Nora Elettrodi S.p.A., Italy	49/2005
139957	Janssen Pharmaceutica N.V., Belgium	1235/2005
139958	Unilever PLC., United Kingdom	406/2006

139959	Eli Lilly and Company, USA	161/1996
139960	Mitsubishi Tanabe Pharma Corporation, Japan	1126/2003
139961	Wyeth, USA	279/2004
139962	1.Mrs. Naseem Fatima Usmani, 2.Miss. Tooba Haq, 3.Mr. Ghulam Husain Shaikh, PCSIR, Karachi, Pakistan	934/2005
139963	Borgwarner Inc., USA	952/2006
139964	Mitsubishi Tanabe Pharma Corporation, Japan	1306/2006
139965	Sanofi-Aventis U.S. LLC., USA	1632/2006
139966	Boehringer Ingelheim International GmbH., Germany	87/2007
139967	Daiichi Pharmaceutical Co. Limited, Japan	256/2007
139968	Sanofi-Aventis, France	543/2007
139969	Sanofi-Aventis, France	544/2007
139970	SmithKline Beecham Corporation, USA	959/1999
139971	F. Hoffmann-La Roche AG., Switzerland	720/2001
139972	Mitsubishi Tanabe Pharma Corporation, Japan	694/2002
139973	Aventis Pharma S.A., France	834/2002

139974	The Procter & Gamble Company, USA	13/2003
139975	AstraZeneca AB, Sweden	522/2003
139976	Chiesi Farmaceutici Spa., Italy	267/2005
139977	Ansaldo Segnalamento Ferroviario S.p. A., Italy	498/2005
139978	Tanabe Seiyaku Co., Limited, Japan	750/2006
139979	Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt., Hungary	1322/2006
139980	SmithKline Beecham p.l.c., England	357/2000
139981	Sumitomo Chemical Company, Limited., Japan	11/2005
139982	Akzo Nobel N.V. Netherland	265/2005
139983	Merck & Co. Inc., USA	595/2005

**(Muhammad Nabi-ur-Rehman)**  
ASSISTANT CONTROLLER  
Tel: 9215500